arrow
D

Deepali Kumar

University Health Network
H指数:71
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AS01E-adjuvanted RSV pre-F protein vaccine in adults with lung or kidney transplant: a phase 2b randomized trial

AS01E佐剂RSV前F蛋白疫苗在肺部或肾脏移植成人中的2b期随机试验

2026-11-130
OA
Indian Society of Organ Transplantation Consensus Recommendations on Latent Tuberculosis in Kidney Transplantation

印度器官移植学会关于肾移植中潜伏性结核的共识建议

2026-11-050
PRE
Vaccination and Safe Living Strategies for Solid Organ Transplant Candidates and Recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

实体器官移植候选者和受者的疫苗接种与安全生活策略:美国移植学会传染病实践社区指南

2026-08-220
PRE
Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study

克 Lazakizumab 在慢性活动性抗体介导的肾移植排斥反应治疗中的应用:IMAGINE III 期、随机、双盲、安慰剂对照研究的结果

2026-04-240
OAAI
Impact of Controlled Hypothermic Preservation On Early Outcomes in Heart Transplant Recipients

控制性低温保存对心脏移植受者早期结局的影响

2025-12-100
PRE
Moving Beyond the Perfect Donor An Interdisciplinary Approach to Optimizing Donor Utilization

超越完美供者:优化供者利用的跨学科方法

2025-12-012
OAAI
Herpes zoster frequency and adjuvanted recombinant zoster vaccination after allogeneic hematopoietic cell transplantation

带状疱疹频率及异基因造血细胞移植后的佐剂重组带状疱疹疫苗接种

2025-10-280
PRE
Recombinant zoster vaccine (RZV) confers persistent immune responses with no safety concerns 4 to 8 years after vaccination of adults with renal transplant

重组带状疱疹疫苗(RZV)在肾移植成人接种后4至8年内可诱导持久的免疫应答,且无安全性问题。

2025-10-010
OAAI
Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: An Interventional Cohort Study

含佐剂的呼吸道合胞病毒疫苗在高风险移植受者中的安全性和免疫原性:一项干预性队列研究

2025-09-260
OAAI
A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation

一种基于细胞介导免疫的移植后巨细胞病毒感染预后评分

2025-07-080
OAAI
Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T-Cell Activity

SARS-CoV-2 JN.1在既往感染过Omicron的移植受者中引起的纵向固有和异源适应性免疫反应:有限的中和作用但CD4+ T细胞活性强

2025-07-020
OA